Off-the-Shelf Cancer Vaccine Works as Well as Personalized Versions in Mouse Breast Cancer | Research

The takeaway

A shared frameshift peptide vaccine reduced tumors and metastases as effectively as personalized cancer vaccines in mice, potentially eliminating the need for custom vaccine manufacturing.

Shared = Personal efficacy
Off-the-shelf FAST vaccine matched personalized cancer vaccines in tumor reduction and metastasis control in mice

What the researchers found

Both personal cancer vaccines (PCVs) and the shared FAST vaccine reduced primary tumor incidence, tumor growth, and lung metastases as monotherapies and in combination with anti-PD-L1/CTLA-4 checkpoint inhibitors. The FAST vaccine induced robust T-cell responses.

Why it matters

Personalized cancer vaccines are expensive, slow to produce, and not feasible for all patients. If shared antigen vaccines work as well, cancer immunotherapy could become accessible to far more patients.

The numbers in context

200 FSP microarray; top 10 peptides per vaccine; both PCV and FAST reduced tumors and metastases; combined with anti-PD-L1 and anti-CTLA-4

How the study worked

Mouse mammary cancer model (4T1) with frameshift peptide microarray screening. Compared personal vaccines (top 10 per mouse) vs shared FAST vaccines (top 10 across all mice). Evaluated with/without checkpoint inhibitors. Measured tumor clearance, metastases, and immune response via ELISPOT, ELISA, and flow cytometry.

Who was studied

4T1 breast cancer model mice

What this study cannot tell us

Mouse model only — human tumors are more heterogeneous. The 4T1 model may not represent all solid tumor types. Sample sizes not clearly reported. RNA-based frameshift antigens in human cancers need validation.

How to read the evidence

Preliminary — promising mouse model results but no human data yet. The 4T1 model is well-established but represents only one tumor type.

When this study was published

Published in 2020; frameshift neoantigen vaccines remain an active area of research with growing clinical interest.

The bigger picture

This work addresses a major bottleneck in cancer immunotherapy — the cost and complexity of personalized vaccines. By identifying shared antigens from predictable RNA errors rather than DNA mutations, it opens a path to mass-produced cancer vaccines.

Questions still open

Do human tumors share enough frameshift peptide antigens to make FAST vaccines broadly effective?
How does the FAST approach perform against tumor types with different mutation burdens?
What is the optimal combination strategy with checkpoint inhibitors for FAST vaccines?

Common questions

What are frameshift peptides and why do they matter for cancer vaccines?

Frameshift peptides are abnormal protein fragments created when cells make errors reading RNA. Cancer cells produce these more frequently, making them recognizable targets for the immune system — and because they come from predictable errors, they can be identified in advance.

Why would a shared vaccine be better than a personalized one?

Personalized cancer vaccines require sequencing each patient's tumor, predicting antigens, and manufacturing a one-time vaccine — a process taking weeks and costing tens of thousands of dollars. A shared vaccine could be mass-produced and available immediately.

Read the original research

Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.

BMC immunology, 21(1), 25

View on PubMed ↗Publisher’s paper ↗

Citation

Peterson, Milene; Murphy, Sierra Nicole; Lainson, John; Zhang, Jian; Shen, Luhui; Diehnelt, Chris W; Johnston, Stephen Albert. (2020). Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.. BMC immunology, 21(1), 25. https://doi.org/10.1186/s12865-020-00350-3